Comparision of the effect of subconjunctival injection of Bevacizumab and Mitomycin in outcome of Ahmed Glaucoma Valve (AGV)
Phase 3
Recruiting
- Conditions
- uncontrolled glaucoma.Glaucoma secondary to other eye disorders, unspecified eye, severe stageH40.50X3
- Registration Number
- IRCT20210521051355N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Uncontrolled glaucoma with full medications
First shunt candidate patients
Exclusion Criteria
Under 18 years old patients
Secondary neovascular glaucoma due to tumor or uveitis
Under 6 month follow up
Previous shunts
pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IOP changes after Ahmed valve implantation with sub-conjunctival injection of bevacizumab or mitomycin. Timepoint: IOP measurement before surgery, 1, 7, 30 days and 3, at least 6 month after surgery and in the last follow up after surgery. Method of measurement: Goldman tonometer.
- Secondary Outcome Measures
Name Time Method umber of glaucoma medication after surgery. Timepoint: Baseline,first day,one week,first month,three months,6 months and last follow up. Method of measurement: counting the number of antiglaucoma drugs.;Complications in each group. Timepoint: first day,First week,first month,three months,6months after surgery. Method of measurement: qualitative and descriptive.